• October 9, 2020
  • 0

(FILES) In this file undated handout image obtained August 11, 2020, courtesy of the National Institute of Allergy and Infectious Diseases(NIH/NIAID), shows a transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient,captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. – The US biotech firm Eli Lilly on October 7, 2020 announced it was seeking an emergency use authorization (EUA) for its lab-produced antibody treatments against Covid-19, after early trial results showed they reduced viral load, symptoms and hospitalization rates.”Our teams have worked tirelessly the last seven months to discover and develop these potential antibody treatments,” said Daniel Skovronsky, Lilly’s chief scientific officer. (Photo by Handout / National Institute of Allergy and Infectious Diseases / AFP) / RESTRICTED TO EDITORIAL USE – MANDATORY CREDIT “AFP PHOTO /NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/HANDOUT ” – NO MARKETING – NO ADVERTISING CAMPAIGNS – DISTRIBUTED AS A SERVICE TO CLIENTS (Photo by HANDOUT/National Institute of Allergy an/AFP via Getty Images)

Upstate News Headlines

PHP Code Snippets Powered By : XYZScripts.com